MARKHAM, ON, Nov. 25 /PRNewswire/ - Cytochroma today announced that Charles W. Bishop, PhD, President and CEO, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care Conference. The presentation will take place at 9:10 am EST on Wednesday, December 2, 2009 at the New York Palace Hotel in New York City.
About Cytochroma
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD. CTA018 Injection is being developed in partnership with Mitsubishi Tanabe Pharma Corporation for the U.S. and Asian markets, and Cytochroma retains co-promotion rights for this product in the U.S. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.
For more information about Cytochroma, please visit www.cytochroma.com.
CONTACT: Cytochroma Investors: Gordon Ngan, Executive Director, Corporate
Development, Tel: (905) 479-5306 ext. 333, gngan@cytochroma.com; Cytochroma
Media: Robert Stanislaro (FD), Tel: (212) 850-5657,
robert.stanislaro@fd.com
